In our ever-aging population, advances in basic cardiac care that have extended our average life expectancy have also left more people living with chronic cardiac disease than ever before. In the United States alone, nearly 4.9 million people suffer from heart failure, yet of the 500,000 new patients diagnosed annually, fewer than 3000 are offered transplantation due to limitations of age, comorbid conditions, and donor availability. Therapeutic limitations have left a significant number of these patients and their physicians searching for alternate options. Despite improvements in the medical management of congestive heart failure (CHF), over 50% of patients continue to die within 3 years of presentation. 1,2 Those with CHF and mitral regurgitation (MR) have a life expectancy of less than 12 months. This clinical deficiency has led to the development of mitral reconstruction as a surgical alternative for the treatment of heart failure.
In our ever-aging population, advances in basic cardiac care that have extended our average life expectancy have also left more people living with chronic cardiac disease than ever before. In the United States alone, nearly 4.9 million people suffer from heart failure, yet of the 500,000 new patients diagnosed annually, fewer than 3000 are offered transplantation due to limitations of age, comorbid conditions, and donor availability. Therapeutic limitations have left a significant number of these patients and their physicians searching for alternate options. Despite improvements in the medical management of congestive heart failure (CHF), over 50% of patients continue to die within 3 years of presentation. 1,2 Those with CHF and mitral regurgitation (MR) have a life expectancy of less than 12 months. This clinical deficiency has led to the development of mitral reconstruction as a surgical alternative for the treatment of heart failure.
Mitral Reconstruction
Mitral regurgitation is a significant complication of end-stage cardiomyopathy and it affects almost all CHF patients as a preterminal event. Its presence is associated with progressive ventricular dilatation, an escalation of CHF symptomatology, and significant reductions in the long-term survival of these patients. 3 The goal of surgical intervention, therefore, is to interrupt this cycle of heart failure through the restoration of normal cardiac physiology and ventricular mechanics.
Fundamental to the management of MR in heart failure is a firm understanding of the functional anatomy of the mitral valve. The mitral valve apparatus consists of the annulus, leaflets, chordae tendineae, and papillary muscles, as well as the entire left ventricle (LV). Thus, the maintenance of chordal, annular, and subvalvular continuity is essential for the preservation of mitral geometric relationships and overall ventricular function. As the ventricle fails, the progressive dilatation of the LV gives rise to MR, which begets more MR and further ventricular dilatation. Incomplete leaflet coaptation and regurgitation develops secondary to alterations in the annular-ventricular apparatus and ventricular geometry. 4 myocardial thinning and dilatation, blunting of the aortomitral angle, widening of the interpapillary distance, increased leaflet tethering, and decreased leaflet-closing forces. All of these combine to result in loss of the zone of coaptation (Figure 1 ). Thus, reconstructing this geometry serves not only to restore valvular competency but also to improve ventricular function. [6] [7] [8] [9] [10] Historically, the surgical approach to MR was mitral valve replacement, yet little was understood of the interdependence of ventricular function and annulus-papillary muscle continuity. 11 Consequently, patients with low ejection fractions who underwent mitral valve replacement with removal of the subvalvular apparatus had prohibitively high mortality rates. 12 In an attempt to explain these outcomes, the concept of a beneficial "pop-off" effect of MR was conceived. This idea erroneously proposed that mitral incompetence provided low-pressure relief during systolic ejection from the failing ventricle, and that removal of this effect through mitral replacement was responsible for deterioration of ventricular function. Consequently, mitral valve surgery in patients with heart failure was discouraged. Renewed appreciation of the importance of subvalvular integrity in the preservation of postoperative LV function has led to new surgical techniques that have been applicable to patients with heart failure. 13 Preservation of the mitral valve apparatus during mitral surgery has resulted in improved ventricular geometry, decreased wall stress, and improved systolic and diastolic function. 14 Thus, maintenance of chordal, annular, and subvalvular continuity is essential to surgically optimize mitral geometry and overall ventricular function. Moreover, with mitral repair, preservation of both leaflet integrity and the dynamic function of the mitral apparatus has clear long-term functional benefits.
In treating heart failure patients, the most significant determinant of leaflet coaptation and MR is the diameter of the mitral valve annulus. 15 The left ventricular dimension is of less importance in functional MR, as the length of the chordae and papillary muscles are similar in myopathic hearts regardless of whether MR is present. This may explain why undersizing and overcorrecting the mitral annulus during reconstruction not only serves to restore the zone of coaptation, but also permits its effective application to patients with diminished ejection fractions (Figure 2) .
At the University of Michigan, 150 patients with end-stage cardiomyopathy and refractory, severe Figure 3) . All patients were in New York Heart Association (NYHA) class III or IV heart failure despite receiving maximal medical therapy. Patients had severe LV systolic dysfunction, as defined by an ejection fraction of less than 25%, with a mean of 14%. On immediate postoperative echocardiograms, the mean transmitral gradient was 3±1 mm Hg (range, 2-6 mm Hg). The overall operative mortality was 5.3%. There were eight 30-day mortalities: one intraoperative death due to right ventricular failure, one from a cerebrovascular accident, one from a pulmonary embolus, one from CHF, and four from multisystem organ failure. Five patients required intra-aortic balloon counterpulsation, and no patients required other forms of mechanical LV assistance. The duration of follow-up of these patients has been 1-80 months, with a mean of 43 months. There have been 27 late deaths: 12 from sudden ventricular arrhythmias, eight from progression of CHF but without MR, three related to complications from other operative procedures, three who progressed to transplantation, and one suicide. The one, two, and five year actuarial survival rates are 82%, 71%, and 57%, respectively.
MR underwent mitral valve repair with an undersized, flexible annuloplasty ring (
At 24 months, all remaining patients were in NYHA class I or II, and had a mean ejection fraction of 26%. NYHA symptoms were reduced from a preoperative mean of 3.2±0.2 to 1.8±0.4 postoperatively. These improvements paralleled subjective functional improvements reported by all patients. Echocardiographically, there were marked improvements in regurgitant fraction, end-diastolic volume, cardiac output, and sphericity index (Table) . Although significant undersizing of the mitral annulus was employed to overcorrect for the zone of coaptation, no systolic anterior motion of the anterior leaflet or mitral stenosis was noted in these patients.
The technique of undersizing in mitral reconstruction probably avoids systolic anterior motion in these myopathic patients through widening of the aortomitral angle in hearts with increased LV size. Furthermore, acute remodeling of the base of the heart with this reparative technique may also somewhat re-establish the normal geometry and ellipsoid shape of the LV. As evidenced by the decreased sphericity index and LV volumes seen in these patients, the geometric restoration of mitral reconstruction not only effectively corrects MR but also achieves surgical unloading of the ventricle.
Comment
Surgical therapies for the treatment of heart failure continue to evolve. Through improved preoperative management, intraoperative techniques, and postoperative care, the previous association of high mortality with surgical interventions for end-stage cardiomyopathy no longer applies. The combination of optimal medical management and mitral repair can provide cardiomyopathy patients with a long-term result that approaches that of transplantation, without the need for immunosuppression. Through the restoration of mitral competency and ventricular geometry, mitral reconstruction offers an appropriate new treatment strategy for the treatment of end-stage heart failure. 
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